News
Round up: US$11m to accelerate breakthroughs in breast cancer research, world’s first whole-genome and transcriptome test, and more

Femtech World explores the latest developments in business in the world of women’s health.
US$11m to accelerate breakthroughs in breast cancer research
Breast cancer organisation Susan G. Komen has announced today that it is awarding US$10.8m in new research grants to help propel innovation in breast cancer research.
The research grants will support 25 cutting-edge projects at 17 institutions.
Through this research investment, Komen is prioritising metastatic breast cancer, health inequities and the need for more precise, personalised treatment strategies to improve care and outcomes for everyone impacted by breast cancer.
So far, Komen’s 2025 research investment has seen 54 per cent of funding targets metastatic breast cancer, 50 per cent focused on precision medicine to tailor treatments to each patient’s unique biology, 21 per cent invested in addressing disparities to eliminate inequities in breast cancer care and outcomes, and 25 researchers funded, including 10 early-career investigators, representing the next generation of scientific leaders.
Juniper Genomics develops world’s first whole-genome and transcriptome test
Health tech company Juniper Genomics recently announced its public launch alongside a US$4.6m seed round.
Founded by experts in genomics, reproductive medicine, and bioethics, Juniper says its mission is to help patients shorten their IVF journey by offering more clarity and confidence on the first transfer.
Juniper’s proprietary platform combines whole genome and transcriptome sequencing with trio analysis, including both biological parents, to provide the most complete, clinically-relevant, and ethically responsible insights into each embryo’s health.
The single test replaces almost all existing forms of preimplantation genetic testing, and adds analysing thousands of clinically relevant genetic variants linked to IVF failure, miscarriage, and medical conditions after birth.
The test provides a clear, detailed and actionable view of embryo health and viability, screening for specific genetic changes known to cause adverse pregnancy outcomes and serious health conditions.
It is currently rolling out in early adopter clinics across North America.
Berry Fertility launches Smart Compose for patient support
Patient management platform for IVF, IUI, embryo transfer, and egg freezing, Berry Fertility, has announced the launch of its AI-powered Smart Compose tool for patient communications.
Smart Compose is designed to integrate seamlessly into existing workflows and EMRs, supporting care teams without disrupting their day-to-day operations, pulling relevant chart details, reviews patient messages, and references history to create a message draft that clinical staff can review and tweak before responding to patients.
According to the company, Smart Compose is purpose-built for the unique needs of fertility clinics and care teams, drawing on proprietary, vetted fertility content and a medication database developed by Berry Fertility.
Beyond EMR integration, Smart Compose can incorporate staff names, clinic locations, medication preferences, appointment calendars, and preferred educational materials to deliver the most accurate and relevant information.
And while Smart Compose adapts to each provider’s needs, their data remains isolated–ensuring that proprietary workflows are never shared or used to improve any other system. While it can understand patient data via workflow integrations, no AI models are trained on patient data. The result is innovative conversational technology, with safeguarded, secure guardrails.
Progyny adds pelvic floor therapy to its offerings
Women’s health company Progyny has announced that it has added digital pelvic floor therapy to its offering of women’s health solutions.
The therapy offers virtual and in-person support options for treatment and coaching, enabling earlier interventions for pelvic conditions and helping avoid delays that could lead to higher acuity treatments, surgeries, or increased healthcare costs for employers.
Progyny will be offering Origin and Hinge Health to its offering. With Origin, Progyny members can access Origin’s nationwide in-network pelvic floor physical therapy, providing evidence-based treatment for pelvic health needs including common concerns like leaky bladder, painful sex, and postpartum recovery, and more complex conditions including hysterectomy recovery, endometriosis, PCOS, and chronic pelvic pain.
With Hinge Health, members will receive digital care supported by physical therapists specialising in pelvic health and musculoskeletal (MSK) care.
Each individual will follow a personalised plan with guided exercises targeting their unique symptoms, including pelvic pain, a lack of pelvic strength or bladder control, and issues associated with menopause.
US$65m for at-home STI test
Diagnostics company Visby Medical recently raised approximately US$55m in its latest financing round.
According to the company, the funds will accelerate the launch and distribution of Visby Medical’s recently FDA-authorised at-home Women’s Sexual Health Test.
Catalio Capital Management, a leading innovative healthcare investment firm, will enhance Visby Medical’s market reach and operational capabilities. As part of the funding round, Catalio Partner Isaac Ro, will join Visby Medical’s board as an observer.
Chuck Alpuche, Chief Operating Officer at Imperative Care, former EVP and Chief Operating Officer at Insulet Corporation, and senior executive at PepsiCo, will also join Visby Medical’s board as an independent director.
According to Visby Medical, its at-home Women’s Sexual Health Test is the first single-use, disposable PCR diagnostic that delivers results within 30 minutes through a connected smartphone app.
Upon receiving positive results, users are connected with telemedicine providers for consultation and treatment, enhancing healthcare accessibility and privacy. The product will be available starting July 2025 through major direct-to-consumer channels.
Gates Foundations awards US$1.9m for preeclampsia treatment
Beech Biotech has received a grant of US$1.9m from the Bill and Melinda Gates Foundation to advance its preeclampsia treatment.
The company is developing “mother only” monoclonals to treat complications of pregnancy, and, according to Beech Biotech, its lead asset – MOm303 – binds and eliminates maternal sFlt-1, targeting a key driver of disease pathology.
The company has said that the funding will help advance the asset for IND-approval.
€4.5m raised for pelvic organ prolapse device
Medical device company Escala Medical has been granted €4.5m to support commercialisation activities for Medit – the company’s pelvic organ prolapse device.
The FDA-cleared device enables the restoration of pelvic floor function within 10 minutes using an incision-free, outpatient procedure.
The funds were awarded from the European Innovation Council (EIC) and other investors.
According to the company, the funds will support expansion into Europe and further international growth in Southeast Asia.
Fertility
Spain football federation partnership to offer players egg-freezing and fertility treatment

Spain’s football federation will offer national team players egg-freezing and fertility treatment through a clinic partnership running until 2029.
The agreement with the Tambre clinic in Madrid will give Spain’s World Cup winners more options to pursue motherhood when they feel the time is right.
The Royal Spanish Football Federation (RFEF) said the agreement covers all national team players, including the futsal team, as well as Primera Division referees and assistants and all other federation employees.
It is the latest policy introduced by the RFEF as it seeks to lead the way in work-life balance and maternity protection.
The federation has also introduced measures allowing players to travel with their children during major tournaments. The scheme was extended to the men’s team during their successful World Cup campaign in North America this past summer.
RFEF president Rafael Louzán said: “If Spain and its national teams are the best in the world on the pitch, they must also be the best in matters such as work-life balance.
“This is a new, comprehensive and pioneering benefit that extends to all federation employees. Today is a great day for the entire Spanish football family.”
The agreement followed a direct request from players after discussions with national team captains, including London City Lionesses midfielder Alexia Putellas.
Putellas told Spanish outlet El País: “As a group of captains, we had a concern — because experiencing a World Cup is vital for a player — regarding the difficulty of reconciling that with the desire to become a mother.”
“It’s a desire I didn’t originally have but developed some time ago.
“Thanks to the incredible work done by the federation, an agreement has been reached with a clinic allowing us to freeze our eggs while we are still active players, for as long as we wish.
“For me, this is a huge step forward; the federation understands that you are serving your country in a way that runs counter to your biological clock — that you can’t simply pause your career to become a mother because you need your body to do your job.”
The announcement follows Chelsea becoming the first Women’s Super League club to offer similar fertility treatment options to its players.
The move has also drawn criticism.
Spanish triple jumper Ana Peleteiro-Compaoré Brión said on Instagram: “The problem obviously isn’t freezing eggs.
“The problem is: why does the institution these women work for have an interest in financing them to delay their motherhood?
“And here there’s a problem that for me changes absolutely everything.
“Is this measure intended to make it easier for women to be mothers or is it intended to make it easier for them not to be while they’re playing?”
Spain are the current world champions in both the women’s and men’s games.
The women will attempt to defend their title at the 2027 World Cup in Brazil next summer.
Menopause
High street bakery chain Gail’s reveals menopause plan

Gail’s has unveiled a menopause action plan offering new workplace support to thousands of staff ahead of legal reforms due in 2027.
The high street bakery chain will offer new benefits including 24/7 digital GP access and a new employee assistance programme, according to The Times.
It will also explore new online training for staff, including specific training for management.
Gail’s people director Miranda Burgum told The Times: “All we’re trying to do is talk freely and for it not to be a forbidden subject. It’s helping our managers and teams understand that this isn’t a taboo.”
“We’re going to develop the education with our managers, so it will be threaded through all our policies
“It will look at induction training, it will look at the types of people we need to make sure that we make reasonable adjustments for.
“And if somebody needs some sort of risk assessment, we’re going to be looking at [that].”
The move comes ahead of reforms due to be introduced in spring 2027 under the Employment Rights Act.
UK employers with 250 or more employees will be legally required to publish and update official menopause action plans.
The plans are intended to support employers to take effective action to improve workplace gender equality and support employees experiencing menopause.
Fertility
Paracetamol use may impact future fertility, studies suggest

Paracetamol use in pregnancy was not linked to autism or ADHD, while separate research found reproductive differences in girls exposed before birth.
One study analysed health records from more than 120,000 children and found no increased risk of autism following prenatal paracetamol exposure.
A separate analysis of nearly 100,000 children also found no increased risk of ADHD among those born to mothers who used the painkiller during pregnancy.
Researchers from the Hong Kong Hospital Authority examined electronic health records covering pregnancies between January 2001 and December 2023.
The autism analysis included 124,333 children, who were nine years old on average and split almost evenly between males and females. There were 3,445 autism diagnoses, representing 2.8 per cent of the group.
The ADHD analysis involved 97,285 children, who were seven years old on average and also split evenly between males and females. There were 5,168 ADHD diagnoses, representing 5.3 per cent.
Women prescribed paracetamol during pregnancy were more likely to be older and have pre-existing conditions including psychiatric disorders, as well as reasons for taking the drug such as infection, fever or chronic pain.
No association was found between prenatal paracetamol exposure and either autism or ADHD.
The findings did not differ according to the trimester in which paracetamol was taken or whether use was intermittent or daily. Advanced maternal age, defined as pregnancy in women over 35, did not alter the findings.
The researchers wrote: “Paracetamol remains a safe and essential analgesic [pain reliever] and antipyretic [fever reducer] during pregnancy, whereas alternatives, such as NSAIDs and opioids carry well-documented risks.
“Unwarranted reluctance to use paracetamol could lead to undertreatment of pain and fever, or the use of more harmful alternatives, both posing risks to the pregnancy and developing fetus.”
The authors said women should assess paracetamol use with guidance from their doctor.
A separate study involving 685 pregnant women without pre-existing conditions and 302 infant daughters found associations between prenatal paracetamol exposure and differences in reproductive organs and hormone levels.
Researchers from Copenhagen University Hospital enrolled the women during their first trimester and assessed them during the first trimester, third trimester and again when their babies were three months old.
At around three months, infants experience a temporary rise in reproductive hormones sometimes called mini-puberty.
Pregnant participants completed questionnaires every two weeks about their use of pain medicines including paracetamol. Infant girls underwent ultrasound scans of their reproductive organs and blood tests to measure hormone levels.
Researchers also examined a separate group of 1,210 girls followed from infancy to adolescence whose mothers reported paracetamol use during the third trimester.
Three-month-old girls exposed to paracetamol before birth had an average 40 per cent smaller ovarian volume, 13 per cent smaller uterine volume and 23 per cent fewer ovarian follicles.
Girls exposed during the first trimester also had lower levels of Anti-Müllerian hormone, a marker of ovarian function.
Among the older girls, those exposed before birth were more likely to have smaller uteruses at puberty and smaller ovaries during their teenage years.
Dr Margit Bistrup Fischer, lead study author and postdoctoral researcher in the Department of Growth and Reproduction at Rigshospitalet hospital in Denmark, said: “Animal studies have demonstrated that impaired formation of ovarian follicles can lead to reduced fertility and earlier reproductive aging.
“Whether the differences observed in our study have implications for fertility and age at menopause in humans remains unknown and will require long-term follow-up of the girls in our cohort.”
She cautioned that women who had used paracetamol during pregnancy “should not be alarmed by our findings”, as the study found associations rather than direct causation and outcomes for individual women and children are unclear.
“Importantly, our study does not evaluate whether [acetaminophen] causes reproductive problems, nor does it provide evidence that prenatal exposure affects future fertility or age at menopause,” she said.
“Although we observed similar associations in an independent cohort, long-term follow-up is needed to determine whether these early-life differences have any clinical significance later in life.”
Entrepreneur1 week agoKOVE Medical raises €1.7 million to improve safety of foetal surgery
Pregnancy1 week agoUK study aims to transform maternity care for high-risk pregnancies
Fertility21 hours agoParacetamol use may impact future fertility, studies suggest
Mental health2 weeks agoPMDD after SSRIs or hormones: Why the brain may be the missing treatment target
Entrepreneur4 days agoLast chance to save on Women’s Health Week and Women’s Sport Summit: Early Bird pricing ends 11 September
Diagnosis2 weeks agoArk Surgical secures further institutional backing to accelerate US expansion
Hormonal health1 week agoMenopause hormone treatment may ease brain fog, study suggests
Motherhood2 weeks agoThousands of UK women develop undiagnosed PTSD after childbirth each year – study










